Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13086MR)

This product GTTS-WQ13086MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13086MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10716MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ8335MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ15260MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ15936MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ4804MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ10743MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ3133MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ5343MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW